Key facts
- It has raised $5.8M; the latest was IPO ($10K) in Jul 2024.
- Notable investors include KB Investment, Shinhan Venture Investment, HG Initiative, KDB Capital, Daesang Holdings — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for AmtixBio
- ·The full record, as it builds
Funding rounds
No funding rounds for AmtixBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AmtixBio
Developer of antifungal drugs intended to treat fungal infections and offer natural antibacterial cosmetics. The company specializes in drug development in the field of antifungal drugs and developing therapeutic agents for diseases and inflammation caused by microorganisms, enabling people to avail of fungal infection treatments at affordable prices.
- Sector
- Healthcare
- HQ
- Gyeonggi-do, South Korea
- Founded
- 2015
- Employees
- 24
- Website
- amtixbio.com/
- Ownership
- Privately Held (backing)
AmtixBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AmtixBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AmtixBio in its N-PORT filings yet. We sweep new filings monthly.